non-small cell lung cancer
KSQ Therapeutics Gets FDA Clearance to Begin Phase I/II Trial of CRISPR-Cas9-Edited TIL Therapy
The firm will evaluate its autologous tumor-infiltrating lymphocyte therapy candidate in melanoma, head and neck cancer, and non-small cell lung cancer.
GenDx, OSE Immunotherapeutics Ink Deal to Develop NGS CDx for Epitope-Based Cancer Vaccine
Under the deal, GenDx will develop and validate a companion diagnostic test for high-resolution typing of HLA-A*02 based on its IVDR-registered NGS products.
Janssen Seeking FDA Approval for Rybrevant-Chemo in EGFR-Mutated NSCLC After Prior Tagrisso Therapy
The firm filed a supplemental biologics licensing application seeking approval for the combination based on data from the Phase III MARIPOSA-2 clinical trial.
FDA Approves BMS's Augtyro for Advanced ROS1-Positive NSCLC
The approval is based on results from the Phase I/II TRIDENT-1 clinical trial of Augtyro in both TKI-pretreated and TKI-naïve ROS1-positive NSCLC.
Apollomics Vebreltinib Approved in China for MET-Altered NSCLC
The NMPA approved the c-MET inhibitor based on results from a Phase II study in Chinese patients demonstrating a 75 percent response rate.